China’s NMPA administration accepts Biologics License Application for PADCEV plus Keytruda in Muscle-Invasive Bladder Cancer

Hengrui ADC innovative drug Ruikang Trastuzumab new indication marketing application accepted and included in priority...

InnoCare Pharma announced that the first patient dosing in the clinical trial of ICP-B208, its...

Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi...

Biocytogen and Whitehawk Therapeutics enter global collaboration for bispecific antibody ADC development

RyboDyn partners with U.S. Department of War to advance AI-discovered ADC therapies for Lung cancer